Paniagua CGL, Monroy PE, Negrete AE, Vaca PS

Language: English
References: 19
Page: 65-68
PDF size: 77.01 Kb.

ABSTRACT

Eighty Candida albicans strains, isolated from throat of patients at the Universitary Clinic of the Faculty of Superior Studies Iztacala of the National Autonomous University of Mexico, were analyzed. They were identified by microscopic and colony morphologies, germ tube test, and by auxanogram and zimogram. Minimal inhibitory concentrations (MIC) of 5-fluorocytosine, miconazole and amphotericin B were determined by microtiter broth dilution. MIC frequency distribution of 5-fluorocytosine showed a single peak (0.25-8.0 µg/ml), with 65% susceptible strains (MIC ≤ 1.0 µg/ml) and 35% intermediate susceptible strains (MIC = 1.1-8 µg/ml). MIC frequency distribution of miconazole was threemodal with 6.25% susceptible (MIC = 1.562 µg/ml), 48.75% intermediate susceptible (MIC = 3.125-12.5 µg/ml), and 45% resistant (MIC = 25-50 µg/ml) strains. All strains were susceptible to amphotericin B (MIC= 0.0156-0.125 µg/m). These results shows that amphotericin B was the more active antimycotic, followed by 5-fluorocytosine, against the strains analyzed, and that miconazole was the less effective one.

REFERENCES

1. Anaissie, E.J., G.P. Bodey and M.G. Rinaldi. 1989. Emerging fungal pathogens. Eur. J. Clin. Microbiol. Infect. Dis. 8:323-330.

2. Banerjee, S.N., T.G. Emori, D.H. Culver, R.P. Gaynes, W.R. Jarvis, T. Horan, J.R. Edwars, T. Tolson, T. Henderson and W.J. Marones. 1991. The National Nosocomial Infections Surveillance System. Secular trends in nosocomial primary bloodstream infections in the United States, 1980-1989. Am. J. Med. 91 (Suppl. 3B): 86S-89S.

3. Barchiesi, F., A.L. Colombo, D.A. McGough, A.W. Fothergill, and M.G. Rinaldi. 1994. In vitro activity of new antifungal triazole, D0870, against Candida albicans isolates from oral cavities of patients infected with human immunodeficiency virus. Antimicrob. Agents Chemother. 38:2553-2556.

4. Batura-Gabryel, N., U. Wiezorec and W. Mlynaiczyk. 1997. In vitro susceptibility of antifungal agents of Candida strains isolated from patients with various diseases of the respiratory tract. Pneumonol. Alergol. Pol. 65: 355-359.

5. Conly, J., R. Rennie, J. Johnson, S. Farah and L. Hellman. 1992. Disseminated candidiasis due to amphotericin B-resistant Candida albicans. J. Infect. Dis. 165:761-764.

6. Dick, J., W. Merz and R. Sarai. 1980. Incidence of polyene resistant yeast recovered from clinical specimens. Antimicrob. Agents Chemother. 18:158-163.

7. Drouhet, E. and B. Dupont. 1987. Evolution of antifungal agents: Past, present and future. Rev. Infect. Dis. 9 (suppl. 1): S4-S14.

8. Fan-Harvard, P., D. Capano, S.M. Smith, A. Mangia and Eng R.H.K. 1991. Development of resistance in Candida isolates from patients receiving prolonged antifungal therapy. Antimicrob. Agents Chemother. 35:2302-2305.

9. Galgiani, J.N, D.J. Drutz, D.S. Feingold, T.M. Kerkering, L.R. McCarthy, M.A. Saubolle and J.C. Sherris. 1985. Committee report. Antifungal susceptibility testing. National Committee for Clinical Laboratory Standards. Villanova. Pa. 5:433-481.

10. Gallis, R, R.H. Drew and W.W. Pickard. 1990. Amphotericin B: 30 years of clinical experience. Rev. Infect. Dis. 12: 308-329.

11. Hernández, M.L., C. Gil, J. Pla and C. Nombela. 1998. Induced expression of Candida albicans multidrug resistance gene CDR1 in response to fluconazole and other antifungals. Yeast 14:517-526.

12. Law, D., C.B. Moore, H.M. Wardle, L.A. Ganguli, M.G. Keaney and D.W. Denning. 1994. High prevalence of antifungal resistance in Candida spp. from patients with AIDS. J. Antimicrob. Chemother. 34:659-668.

13. Maksymiuk, A.W, S. Thongprasert, R. Hopfer, M. Luna, V. Fainstein and G.P. Bodey. 1984. Systemic candidiasis in cancer patients. Am. J. Med. 77: 20-27.

14. Monteil, R.A., I. Madinier, and Y. Le Fichoux. 1997. In vitro antifungal resistance of oral Candida albicans strains in non-AIDS patients. Oral Microbiol. Immunol. 12: 126-128.

15. Radetsky, M., R.C. Wheeler, M.M. Roe and J.K. Todd. 1986. Microtiter broth dilution method for yeast susceptibility testing with validation by clinical outcome. J. Clin. Microbiol. 24:600-606.

16. Soll, D.R., R. Galask, J. Schmid, C. Hanna, H. Mac and B. Morrow. 1991. Genetic dissimilarity of commensal strains of Candida spp. Carried in different anatomical locations of the healthy women. J. Clin. Microbiol. 29: 1702-1710.

17. Vazquez, J.A., M.T. Arganoza, D. Boikov, S. Yoon, J.D. Sobel and R.A. Akins.1998. Stable phenotypic resistance of Candida species to amphotericin B conferred by preexposure to subinhibitory levels of azoles. J. Clin. Microbiol. 36:2690-2695.

18. White, T.C. 1997. Increased mRNA levels of ERG16, CDR and MDR1 correlate with increases in azole resistance in Candida albicans isolates from a patient infected with human immunodeficiency virus. Antimicrob. Agents. Chemother. 41:1482-1487.

19. Yoshida, T., K. Jono & K. Okonogi. 1997. Modified agar dilution susceptibility testing method for determining in vitro activities of antifungal agents, including azole compounds. Antimicrob. Agents Chemother. 41(6):1349-1351.